Search

Search Constraints

You searched for: Author/Creator Kraemer, D.

Search Results

1. Abstracts from the 4th ImmunoTherapy of Cancer Conference: Prague, Czech Republic. 20–22 March 2017. (20th March 2017)

2. Conversion of AML-blasts to leukemia-derived dendritic cells (DCleu) in 'DC-culture-media' shifts the (serum) chemokine-release profile to a more 'inflammatory' (in culture) going along with improved antileukemic T-cell-reactivity. (March 2019)

4. Modulation of AML-blasts with clinically approved response modifiers to leukemia-derived dendritic cells (DCleu) ex vivo: DC-, T-cell- and cytokine profiles are predictive for antileukemic T-cell reactivity. (March 2019)

5. Serum Chemokine-release Profiles in AML-patients Might Contribute to Predict the Clinical Course of the Disease. (18th May 2020)

6. Standard normoxic versus physiological hypoxic culture of AML patients' (pts) whole blood (WB) samples with immune modulatory kits yields comparable proportions of dendritic cells and functional results. (March 2018)